DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02909933

CompletedPhase 4

Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Obesity / overweight, PCOS

Key I/E criterion

•Female

Primary endpoint

•Body weight, absolute change (kg)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02909933
Org study IDCOMBO - LIRA 3

Timeline

Milestones

Study first posted2016-09-21estimated
Last update posted2016-09-21estimated
Study start2015-07 (month precision)
Primary completion2015-10actual (month precision)
Study completion2015-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightPCOS

Eligibility

Who can enroll

Minimum age18 Years
Maximum age55 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•18 years old to menopause
•polycystic ovary syndrome (NICHD criteria)
•BMI of 30 kg/m² or higher

Exclusion criteria

•type 1 or type 2 diabetes mellitus
•history of carcinoma
•Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
•personal or family history of MEN 2
•significant cardiovascular, kidney or hepatic disease
•the use of medications known or suspected to affect reproductive or metabolic functions
•the use of statins, within 90 days prior to study entry

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

2 endpoints
Primary/protocol endpoint

The main outcome was change in body weight.

Time frame:Patient's body weight was measured at the base point and after 12 weeks of clinical trial.

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

The secondary outcome was change in body mass index (BMI)

Time frame:Patient's body weight were measured at the base point and after 12 weeks of clinical trial. Patient's height was measured at the base point.

BMI, change

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.